“Our kernel of an idea to train a lens on the forgotten yet heroic women of science has resonated. Enthusiasm for this project from a wide array of STEM experts has been remarkable. We’re especially pleased to announce that Maria Klawe, President of Harvey Mudd College, was one of the first to endorse the project and has signed on as chair of our Advisory Board.”— Katie Hafner
“Lost Women of Science is paying it both ways – forward as well as back. Revisiting vital history, Lost Women of Science will also inspire young women working their way through the STEM pipeline, which is a core part of our mission. I am proud of the team and to serve with the other phenomenal women on the Lost Women of Science Advisory Board.”— Maria Klawe
Board Chair. Dr. Klawe, a renowned mathematician and computer scientist, left Princeton in 2006, where she was Dean of engineering and applied science, to begin her tenure as Harvey Mudd College’s fifth president in 2006. She is the first woman to lead the College since its founding in 1955.
Dr. Grogan is the Chief Scientific Officer at Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases. She is a renowned scientist in the fields of immunology, oncology and cell therapy with over two decades of biotech and life sciences industry experience. She also created and hosted the popular podcast, Two Scientists Walk Into a Bar.
Sian L. Beilock is the eighth President of Barnard College. A cognitive scientist by training, President Beilock previously spent 12 years at the University of Chicago, departing as the Stella M. Rowley Professor of Psychology and Executive Vice Provost. She is committed to raising Barnard’s eminence in math, science, and technology to parallel its renown in the arts and humanities.
Dr. Grais is a successful biotech executive, an Independent Board Member of ICON plc. She has extensive experience in the healthcare field as a physician, entrepreneur and independent board member. Her medical degree is from Yale University, and her law degree is from Stanford University.
Dr. Desmond-Hellmann is the former Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 until 2020 and current Senior Advisor and Board member of the Bill & Melinda Gates Medical Research Institute.
Dr. Sacher, a retired general surgeon, currently serves on the Board of Trustees of Barnard College, the Advisory Board for Columbia University’s Global Mental Health Program, and as a Leadership Fellow at Johns Hopkins University.
Dr. Lyon holds a PhD in Science Education from University of Texas at Austin where she has “taught it all,” including AP Physics, Engineering, and Geology at the high school level, as well as Science and Humanity at UT San Antonio.
Pam Kramer is a 20+ year Silicon Valley product and marketing veteran who most recently is focusing on podcasting. Former CMO of the Cadence13 Podcast Network, where she grew the leading premium podcast network from 30 million downloads/year to over 1.5 billion/year. And launched and grew over 40 podcasts, from TNT, Deepak Chopra, and many others. Now she is excited to be the CMO of Voyager Digital.
Ms. Goodwin is a partner at Perkins Coie LLP, an international law firm. Ms. Goodwin is counsel to the Lost Women of Science Initiative on legal matters. Her interest in the topic of women in S.T.E.M. fields stems in part from observing her husband’s field — paleontology — and hearing stories of women overcoming gender bias to shine.
Daphne Higgs is a partner in Perkins Coie’s Technology Transactions & Privacy group in Silicon Valley, and she plays an integral role within the firm’s Emerging Companies & Venture Capital practice. She is co-chair of the firm’s Women of Color group.
As Dean for Diversity and Community Partnership and Professor of Medicine at Harvard Medical School, as well as Professor of Society, Human Development and Health at Harvard's T.H. Chan School of Public Health, Dr. Reede has a passion for mentoring diverse individuals in the biosciences. Her duties include development and management of a comprehensive program that provides leadership, guidance, and support to promote the increased recruitment, retention, and advancement of diverse students, trainees, and faculty. She is a member of the National Academy of Medicine and a fellow of the American Association for the Advancement of Science.
Sarah Greene is CEO of RapidScience.org and consultant to Aligning Science Across Parkinson's. She served as Executive Director of Cancer Commons, co-founded the Journal of Participatory Medicine (and its society), was Editor-in-Chief of The Scientist, and was Senior Program Director of The New York Times Health vertical and served at the New York Academy of Sciences.
A Professor in the Department of Biology at Boston University, Dr. Templer studies how climate change, air pollution, and urbanization affect forest ecosystems. She has published over 100 papers on a wide range of topics, including how environmental changes affect the ability of forests to sequester carbon, cycle nitrogen, and improve air and water quality. Her research has been highlighted in many media outlets, including NPR, HBO, NBC, CBS, the Boston Globe, Scientific American, and Car Talk.”
The founder and president of Cunningham Collective, a marketing, brand and communication strategy firm dedicated to bringing innovation to market. She is also the author of “Get to Aha!” a seminal primer about corporate positioning. Andy is a much sought after marketing expert in Silicon Valley, having been on the forefront of marketing, branding, positioning and communicating “The Next Big Thing” for over 30 years. She is well known for helping Steve Jobs launch the Macintosh and later working with him at NeXT and Pixar."
As the Executive Vice President for Oncology R&D at AstraZeneca, Susan has global accountability for the Oncology portfolio from discovery through to late-stage development. Since joining AstraZeneca in 2010, Susan has been instrumental in bringing seven new medicines to patients, four of which are now blockbusters. Prior to AstraZeneca, Susan held senior Oncology R&D roles at Bristol-Myers Squibb. A Clinical Oncologist by background, Susan trained in medicine at Manchester and Cambridge Universities and has a PhD from the University of London. She holds an honorary Doctorate of Medical Science from the Institute of Cancer Research and is a Fellow of the Academy of Medical Sciences. Susan serves on the American Association for Cancer Research Board of Directors, the Institute of Cancer Research Scientific Advisory Board and the European Association of Cancer Research Advisory Council; she is also the current Chair of the Board at Definiens AG.